Prosecution Insights
Last updated: November 20, 2026

Rebecca L Anderson, USPTO Patent Examiner

Listed by the USPTO as ANDERSON, REBECCA L

Tech Center 1600 • Art Units: 1626

This examiner grants 74% of resolved cases

Performance Statistics

73.5%
Allow Rate
+13.5% vs TC avg
1,111
Total Applications
+23.4%
Interview Lift
855
Avg Prosecution Days
Based on 1055 resolved cases, 2023–2026

Rejection Statute Breakdown

2.7%
§101 Eligibility
24.3%
§102 Novelty
18.7%
§103 Obviousness
33.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18569721 TREATMENT AND PREVENTION OF DEVELOPMENTAL DISORDERS AND MENTAL DISEASES Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,
18532632 TREATMENT OF MYELOPROLIFERATIVE DISEASES AND DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17790407 COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Non-Final OA The Regents of the University of California
17570997 N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS Final Rejection The Regents of the University of California
19661115 PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE Non-Final OA Compass Pathfinder Limited
19629952 PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE Final Rejection Compass Pathfinder Limited
19110241 SPRAY-DRIED AMORPHOUS SOLID DISPERSIONS AND METHOD FOR PREPARATION Non-Final OA Merck Patent GMbH
18767505 ARYLQUINAZOLINES Non-Final OA Merck Patent GmbH
18215286 INHIBITORS OF TRIM33 AND METHODS OF USE Non-Final OA DANA-FARBER CANCER INSTITUTE, INC.
18288473 MELANIN MATERIALS FOR TISSUE REPAIR Non-Final OA Northwestern University
18845807 NOVEL PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS COMPRISING THE SAME, METHODS OF MAKING, AND METHODS OF TREATING A DISEASE Non-Final OA The Curators of the University of Missouri
18864008 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE Non-Final OA CHINA PHARMACEUTICAL UNIVERSITY
18035502 NOVEL VHL SMALL MOLECULE PROBES Non-Final OA St. Jude Children's Research Hospital, Inc.
18278166 COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE Final Rejection DR. NOAH BIOTECH INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Rebecca L Anderson's allowance rate?

73.5% of resolved applications examined by Rebecca L Anderson were allowed (1,055 resolved cases), compared with 54.6% across Art Unit 1626 over the last five years.

Does an interview help with examiner Rebecca L Anderson?

This examiner's interview lift is +23.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Rebecca L Anderson take to allow a patent?

Applications allowed by Rebecca L Anderson took 855 days on average from filing to allowance.

Which art unit does examiner Rebecca L Anderson work in?

Rebecca L Anderson examines applications in Art Unit 1626 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month